The Dendreon Corp. (DNDN) announced today it has completed the submission of its amended biologics license application (BLA) for Provenge to the U.S. Food and Drug Administration (FDA) (http://tinyurl.com/yzmx9qo).
Dendreon is seeking to have Provenge licensed for men with metastatic castrate-resistant prostate cancer (CRPC). Should the FDA follow the data this time around, Provenge would be the first product in the new therapeutic class known as active cellular immunotherapies.
Given Dendreon's announcement today, I hereby amend one of the statements in my Probabilities and the Financial Markets blog post: Basically, I now believe there is a high probability the FDA will be compelled to OK Provenge as a treatment for patients with metastatic CRPC by May 2 of next year.
Related Blog Posts
Probabilities and the Financial Markets (http://tinyurl.com/yzv7689)
Dendreon's Provenge: Maximum IMPACT (http://tinyurl.com/yzr2dor)
Congressmen Request Probe of FDA's Provenge Delay (http://tinyurl.com/ygfukge)
Sentiment Analysis: How Do You FEEL About It? (http://tinyurl.com/y93o7jy)
Dendreon CFO Pulls a Rabbit Out of the Hat, Again (http://tinyurl.com/yzrg33c)
Synchronicity! And Three Cheers for Ralph M. Steinman! (http://tinyurl.com/ylzxcm6)
Patient Advocates Plan Protest of Dysfunctional FDA (http://tinyurl.com/yk3qwvv)
Hey, Hey, FDA, How Many Dads Did You Kill Today? (http://tinyurl.com/ykuxrw2)
| Make Big Bucks promoting Zacks products on your website! Click here to Learn about Zacks' Affiliate program. |
| Take advantage of quick short-term moves, and profit from price moves in any direction. Trade options under the direction of an expert guide. Try it now and get a 90-day unconditional money-back guarantee. 50% OFF for a limited time! Zacks Options Trader >> |
|
Ride Momentum Stocks to Quick Gains! The market is finally breaking out, creating the perfectd wave for investing in momentum stocks. Zacks is the king of fundamental analysis, but this service also uses technical indicators for the best possible timing. Click here to learn more >>. |
| Zacks Top Ten Stocks for 2011 are now available! This 10-stock portfolio is a well-balanced mix of aggressive and conservative, large and small cap, growth and value. Buy them. Hold them. Watch your gains add up |

Read MackTheKnife's blog in RSS


November 2, 2009
Edited: November 2, 2009
Share This

